By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics developer Exagen Diagnostics said today that it has signed up EndoChoice to promote its genomic tests for bowel disorders to gastrointestinal doctors in the US.

EndoChoice, which specializes in gastroenterology, will market Exagen's gene expression tests for diagnosing inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Albuquerque, NM-based Exagen said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.